With Shares Trading up at $9.50 (SGMO) Sangamo Receives Fast Track Designation…

Amos Gonzales
July 14, 2017

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) notched a 12-month high of $11.80 while $20.00 target is by far the most aggressive out of analysts who are now evaluating SGMO, $8.2 higher than the next highest 52-week price estimate. Three analysts have issued estimates for Sangamo BioSciences' earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.12). Wedbush maintained Sangamo Therapeutics Inc (NASDAQ:SGMO) on Wednesday, September 2 with "Buy" rating. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $56.76 on company shares. Earnings, with 6 analysts believing the company would generate an Average Estimate of $-0.19. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. Zacks Investment Research's EPS averages are an average based on a survey of research analysts that cover Sangamo BioSciences.

Sangamo Therapeutics Inc (SGMO) now has a 14-day Commodity Channel Index (CCI) of 23.63. Next quarter's EPS is forecasted at $-0.29 with next year's EPS anticipated to be $-1.03. The business had revenue of $3.40 million for the quarter, compared to analyst estimates of $4.14 million. Sangamo BioSciences had a negative return on equity of 50.76% and a negative net margin of 380.44%. ValuEngine upgraded shares of Sangamo BioSciences from a "sell" rating to a "hold" rating in a research note on Thursday, June 15th.

Following U.S. election volatility some analysts have updated their recommended target prices on shares of Sangamo BioSciences, Inc. Cowen and Company restated a "buy" rating on shares of Sangamo BioSciences in a research report on Wednesday, March 22nd. For now, SGMO is the toast of Wall Street as its ABR stands at 2.00 with 2 out of 6 analysts rating the stock a buy. Sangamo BioSciences presently has a consensus rating of "Hold" and an average target price of $8.50.

Currently Sangamo Therapeutics (NASDAQ:SGMO)'s shares owned by insiders are 0.1%, whereas shares owned by institutional owners are 53.1%. SGMO share have rallied by 211.48% in percentage terms since the start of the year - and added 29.25% in the last month.

According to Zacks, analysts expect that Sangamo BioSciences will report full year sales of $6.79 million for the current fiscal year, with estimates ranging from $18.00 million to $85.60 million.

Aristocrat jailed for offering money to kill Gina Miller
A peer who offered £5,000 on Facebook for someone to kill the anti-Brexit campaigner Gina Miller has been sent to jail. Ms Miller, 52, had said she found his comments "genuinely shocking" and that they made her feel " violated ".

Sangamo Therapeutics (NASDAQ:SGMO) 52-week high price stands at $9.65 and low price stands at $2.65, its price distance from 52-week high is -1.55% while its distance from 52-week low price is 258.49%. Finding that next big victor may take a lot of research and number crunching with so many stocks trading around all-time highs. The stock traded at a volume of 2.77 million shares. The firm's 50 day moving average is $7.82 and its 200 day moving average is $4.99. Sangamo BioSciences has a 1-year low of $2.65 and a 1-year high of $9.65.

A number of hedge funds have recently modified their holdings of the company. Volume in the last session has increased compared with SGMO's average trading volume. Tudor Investment Corp Et Al purchased a new stake in shares of Sangamo BioSciences during the fourth quarter valued at approximately $201,000. Finally, Teachers Advisors LLC raised its position in shares of Sangamo BioSciences by 4.9% in the fourth quarter. Meeder Asset Management Inc reduced its investment by selling 839 shares a decrease of 58.6% as of 06/30/2017. MA boosted its stake in shares of Sangamo BioSciences by 333.3% in the first quarter. NY now owns 49,713 shares of the biopharmaceutical company's stock worth $152,000 after buying an additional 780 shares during the period.

Price/Earnings to growth ratio for the company is N/A and the stock shows its Price/Sales (ttm) of 42 and Price/Book for the most recent quarter of 5.42.

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., launched on June 22, 1995, is a clinical-stage biotechnology company.

Other reports by BadHub

Discuss This Article